Key result
Concurrent HCM is linked to ~81% higher in-hospital mortality in acute ischemic stroke.
Why the study?
Ischemic stroke is a known complication of hypertrophic cardiomyopathy (HCM), yet little is known about in-hospital outcomes once these patients are admitted with an acute stroke.
Does concurrent hypertrophic cardiomyopathy increase the risk of all-cause in-hospital mortality and length of stay in adults hospitalized with acute ischemic stroke?
Cohort (n=1,566,915)
Yes
Does concurrent hypertrophic cardiomyopathy increase the risk of all-cause in-hospital mortality and length of stay in adults hospitalized with acute ischemic stroke?
Patients hospitalized for acute ischemic stroke with concurrent hypertrophic cardiomyopathy have nearly double the odds of in-hospital mortality and longer hospital stays compared to matched controls, driven by comorbidities like heart failure, renal failure, and coagulopathy rather than atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Acute ischemic stroke with concurrent hypertrophic cardiomyopathy was associated with higher in-hospital mortality; leaves open whether this reflects causal risk or unmeasured confounders.
< .001), longer hospital stays, and higher hospitalization costs compared to those without HCM. In the HCM group, age, congestive heart failure, peripheral vascular disease, renal failure, and coagulopathy were identified as predictors of mortality. In conclusion, we found that patients hospitalized with AIS and concurrent HCM were associated with worse in-hospital outcomes, including higher mortality, longer hospital stays, and increased hospitalization costs. CLINICAL IMPACT: Ischemic stroke is a known complication of hypertrophic cardiomyopathy (HCM), yet we know surprisingly little about how these patients do once they are admitted with an acute stroke. Using a large national inpatient database and a propensity-matched comparison, we found that stroke patients with HCM had nearly twice the odds of dying in the hospital, stayed longer, and had higher hospitalization costs than comparable patients without HCM. One finding we did not expect was that atrial fibrillation, often seen as the main driver of stroke risk in HCM, did not independently predict death in the HCM group. Instead, older age, heart failure, peripheral vascular disease, renal failure, and coagulopathy were tied to mortality. For clinicians, this means HCM itself should be viewed as a high-risk marker in stroke patients. in addition to the presenting rhythm, including atrial fibrillation, coexisting conditions deserve close attention during the admission.
No takes yet. Share an insight, caveat, or question.
Babbili et al. (2026) conducted a cohort in Acute ischemic stroke (n=1,566,915). Concurrent hypertrophic cardiomyopathy (HCM) vs. Hospitalized acute ischemic stroke patients without concurrent hypertrophic cardiomyopathy was evaluated on All-cause in-hospital mortality (OR 1.81, 95% CI 1.53-2.13, p=<0.001). Concurrent hypertrophic cardiomyopathy was associated with higher all-cause in-hospital mortality in acute ischemic stroke patients.
Synapse has enriched 10 related papers. Consider them for comparative context: